Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes

Area of Science:

• Molecular biology
• Gene therapy
• Cancer research

Background:

• Survivin is a key protein promoting cancer cell survival and proliferation.
• Targeting survivin mRNA is a potential strategy for cancer gene therapy.
• Hammerhead ribozymes offer a means to cleave specific mRNA sequences.

Purpose of the Study:

• To design and evaluate hammerhead ribozyme adenoviruses targeting survivin mRNA for cancer therapy.
• To assess the efficacy of these ribozymes in vitro and in vivo.
• To determine the synergistic effects of combining multiple ribozymes.

Main Methods:

• Construction of four hammerhead ribozyme adenoviruses (R1-R4) targeting survivin mRNA.
• In vitro characterization including sequence specificity and cleavage assays.
• In vitro assays for cell proliferation and in vivo studies of tumor growth inhibition in a hepatocellular carcinoma xenograft mouse model.

Main Results:

• Ribozyme adenoviruses successfully suppressed survivin expression, inducing mitotic catastrophe and caspase-3-dependent cell death.
• Adenovirus-mediated ribozyme delivery inhibited tumor growth in a mouse model.
• Co-expression of R1, R3, and R4 ribozymes showed synergistic effects, yielding the most potent anti-cancer activity by targeting multiple survivin transcript forms.

Conclusions:

• Hammerhead ribozyme adenoviruses represent a robust gene therapy strategy against cancer.
• Targeting survivin mRNA with multiple ribozymes offers a potent approach for cancer treatment.
• This gene therapy strategy effectively inhibits tumor growth and induces cancer cell death.